Logo

Zydus Cadila Seeks Approval to Commence P-III Clinical Study of ZyCoV-D

Share this

Zydus Cadila Seeks Approval to Commence P-III Clinical Study of ZyCoV-D

Shots:

  • The company reported that the COVID-19 vaccine is safe- well-tolerated & immunogenic in the P-I/II study & plans to initiate P-III clinical trial in ~30000 volunteers upon receiving necessary approvals
  • The P-II study of ZyCoV-D had been conducted in ~1000 healthy adult volunteers as part of the adaptive P-I/II dose-escalation study
  • The trial has been reviewed by an independent DSMB & reports have been submitted to CDSCO regularly for the update on safety outcome

 ­ Ref: Zydus Cadila | Image: eHealth Magazine

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions